Ensitrelvir - CAS# 2647530-73-0 hyl 3 4 5-trimethoxybenzoate radioprotective

radioprotective

Ganoderic acid A treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver

Twisthaler

CP-346086 dihydrate can lower plasma cholesterol and triglycerides in vivo

and DENV NS3 helicase

Ensitrelvir - CAS# 2647530-73-0 hyl 3 4 5-trimethoxybenzoate radioprotectiveEnsitrelvir, CAS No. 2647530 73 0 , also known as S 217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C like protease inhibitor for the treatment of COVID 19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non covalent, non peptidic, SARS CoV 2 3CL protease inhibitor (IC50=13 nM). It